AzTrials
AzTrials

Metastatic Castration Resistant Prostate CancerPhase 1/2PRINCENCT03658447

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

A Phase 1/2 study testing Pembrolizumab and 177Lu-PSMA in people with Metastatic Castration Resistant Prostate Cancer, run by Peter MacCallum Cancer Centre, Australia at 4 sites in Australia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Pembrolizumab and 177Lu-PSMA
Could I receive a placebo?
No, everyone receives an active treatment
How many people
37 participants
Where
4 sitesAustralia
Study dates
12 Jul 2019to 22 Dec 2022
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must meet the following criteria for study entry:
  • Patient who are at least 18 years of age who have provided written informed consent.
  • Histologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell differentiation.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 (see Appendix 1).
  • Patients must have progressed on prior enzalutamide, abiraterone and/or apalutamide for treatment of prostate cancer.
  • Determination of disease progression on second generation androgen receptor targeted agent determined by the local investigator. Progressive disease is defined by PCWG3 as any one of the following:
Show all 29Show fewer
  • PSA progression: minimum of two rising PSA values from a baseline measurement with an interval of ≥ 1 week between each measurement. The PSA value at screening should be ≥ 1ng/ml.
  • Soft tissue or visceral disease progression as per modified RECIST 1.1 criteria (see Appendix 2)
  • Bone progression: ≥ 2 new lesions on bone scan (Appendix 2)
  • At least 2 weeks since the completion of surgery or radiotherapy prior to registration. Any clinically relevant sequelae from the surgery or radiotherapy must have improved to grade 1 prior to registration.
  • Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone (LHRH) analog (agonist or antagonist). Patients without prior surgical castration must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analog (agonist or antagonist) therapy throughout the duration of study treatment.
  • Serum testosterone levels ≤ 50ng/dL. (≤ 1.75nmol/L) within 28 days before registration.
  • Imaging evidence of metastatic disease documented with either bone scan or CT scan (Appendix 2).
  • Prior prostate cancer vaccine therapy, radiation therapy, systemic therapies, diethylstilboestrol (DES) or other estrogens are allowed up to 28 days prior to trial registration. Note: bicalutamide flutamide or nilutamide must be discontinued within 4 weeks of registration.
  • Significant PSMA avidity on 68Ga/18F-PSMA PET/CT, defined as a minimum uptake of SUVmax 20 at a site of disease, and SUVmax > 10 at other sites of disease ≥10mm (unless subject to factors explaining a lower uptake, e.g. respiratory motion, reconstruction artefact).
  • Patients must have a life expectancy ≥ 24 weeks.
  • Patients must agree to use a highly effective form of contraception for the entire duration of the study plus an additional 120 days (a spermatogenesis cycle) after the last dose of study treatment and refrain from donating sperm during this period (see section 10.3.3).
  • Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled assessments.
  • Patients must have adequate bone marrow, hepatic and renal function documented within 28 days of registration, defined as:
  • Haemoglobin ≥90 g/L independent of transfusions (no red blood cell transfusion in last 4 weeks)
  • White blood cells >3x109/L
  • Absolute neutrophil count ≥1.5x109/L
  • Platelets ≥100 x109/L
  • Total bilirubin ≤1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome.
  • Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) ≤2.5 × ULN or ≤5 × ULN for participants with liver metastases.
  • Serum creatinine ≤1.5 x ULN or a calculated creatinine clearance > 50mL/min (Chronic Kidney Disease Epidemiology (CKD-EPI) equation for patients with creatinine levels above institutional normal.
  • Albumin >30 g/dl
  • International normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.
  • Patients who are deemed by PSMA imaging to have readily accessible disease will be required to consent to 3 serial tumour biopsies - at screening, post combination treatment (at any time between weeks 2-4) and on progression

Who cannot join

  • Site(s) of disease that are FDG positive with low PSMA expression defined by PSMA SUVmax < 10.
  • Previous history or presence of brain metastases or leptomeningeal metastases.
  • Any prior exposure to anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathway.
  • Any prior treatment with cabazitaxel.
  • Any prior exposure to 177Lu-PSMA.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Show all 17Show fewer
  • Patients with active, known or suspected autoimmune disease including Sjogren's syndrome. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are eligible.
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
  • Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.
  • Patients with a condition requiring systemic treatment with either corticosteroids (> 10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Other malignancies within the previous 2-years other than, melanoma in situ, basal cell or squamous cell carcinomas of skin with a > 30% probability of recurrence within 12 months.
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
  • Patient has a known history of Human Immunodeficiency Virus (HIV).
  • Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable for ≥ 4 weeks.
  • Previous history of interstitial lung disease or non-infectious pneumonitis.
  • Recent administration of a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  • Recent administration of the influenza vaccine (within 30 days of registration).

Trial locations and contacts

4 sites in 1 country.

Australia4 sites

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000

  • Box Hill Hospital

    Melbourne, Victoria, 3128

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, 2010

  • Chris O'Brien Lifehouse

    Sydney, New South Wales, 2050

Other trials in Australia

About this study

Official title: Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). 177Lu-PSMA is a compound that binds to the extra-cellular domain of the prostate-specific membrane antigen. Pembrolizumab is an antibody targeted against anti-programmed cell death 1 (PD-1).This is a single arm study where all patients will be treated with 177Lu-PSMA for upto 6 doses and pembrolizumab for upto 35 cycles.

Being tested
Pembrolizumab, 177Lu-PSMA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PembrolizumabDrug

    Also called Keytruda

    200mg Pembrolizumab given 3 weekly for upto 35 cycles

  • 177Lu-PSMADrug

    6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.

Study groups in NCT03658447
Study groupRoleWhat they receive
177Lu-PSMA + PembrolizumabExperimental200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
Receives: Drug: Pembrolizumab; Drug: 177Lu-PSMA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prostate Specific Antigen (PSA) response

    PSA response will be defined as a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response.

    Measured: Through study completion, up until 24 months after the last patient commences treatment.

  2. Incidence of Treatment-Emergent Adverse Events [Safety]

    Safety will be measured by serious adverse events (SAEs) and AEs assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Measured: Through treatment completion, maximum of 24 months

  3. Tolerability

    Tolerability is defined as the time from treatment commencement until treatment discontinuation due to toxicity. Participants who ceased treatment due to reasons other than toxicity will be censored at the time of ceasing protocol treatment and participants who died while on treatment from reasons unrelated to the treatment will be censored at the date of death.

    Measured: Through treatment completion, maximum of 24 months

Secondary outcomes (8)

  1. Radiographic progression free survival

    Measured: Through study completion, up until 24 months after the last patient commences treatment.

  2. PSA-progression free survival

    Time from treatment initiation to the date of PSA progression per PCWG3 or death due to any cause, whichever occurs first. The date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2ng/mL or more from the nadir is documented.

    Measured: Through study completion, up until 24 months after the last patient commences treatment.

  3. Overall survival

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  4. Overall Response Rate by modified RECIST1.1

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  5. Duration of objective tumour response as assessed by modified RECIST 1.1 for soft tissue and PCWG3 for bone lesions

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  6. Time to treatment (TTR) response

    TTR-PCWG3 is defined as the time from treatment initiation to the date of the first documented CR or PR per modified RECIST1.1 for soft tissue and PCWG3 for bone lesions.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  7. Change in pain

    The Brief Pain Inventory - Short Form (BPI-SF) is 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions through the use of a numerical rating scale (NRS). Participants rate the severity of their pain as its "worse", "least' and "average" in the last 24 hours using an 11-point NRS with anchors "no pain'' and ''pain as bad as you can imagine.'' This instrument consists of 2 domains: pain severity and pain interference. The BPI-SF also asks the participants to mark the location of the pain on a body drawing and includes additional questions regarding pain treatment and the extent of pain relief. The BPI-SF will be scored according to the user guide. Higher pain scores is worse outcome.

    Measured: Through treatment completion, maximum of 24 months

  8. Change in Health Related Quality of Life (HRQoL)

    The Functional Assessment of Cancer Therapy - Prostate cancer (FACT-P) provides information about general and disease-specific symptoms. The FACT-P module is a disease-specific 39-item questionnaire that has been validated for the purpose of assessing health-related quality of life (HRQoL) in prostate cancer patients. The FACT-P consists of 5 subscales: Physical Well-Being (7 items), Functional Well-Being (7 items), Emotional Well-Being (6 items), Social Well- Being (7 items), and additional concerns or Prostate Cancer Subscale (PCS) specific to prostate cancer (12 items). FACT-P questions are scored on a 5-point Likert scale from 0 to 4 (0 being not at all and 4 being very much).Scoring of the FACT-P will be based on the user manual. Higher scores means higher quality of life.

    Measured: Through treatment completion, maximum of 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2018
  2. Study start12 Jul 2019
  3. Primary completion22 Dec 2022
  4. Study completion22 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03658447
Sponsor's protocol ID
PeterMac project no. 18/114
Acronym
PRINCE
Status last verified
Jul 2023
First submitted
23 Aug 2018
Last updated
28 Jul 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS. [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. Lancet Oncol. 2026 Apr;27(4):470-479. doi: 10.1016/S1470-2045(26)00017-3.

    PubMed 41926961

  • Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640.

    PubMed 40610228

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Pembrolizumab and 177Lu-PSMA in people with Metastatic Castration Resistant Prostate Cancer, run by Peter MacCallum Cancer Centre, Australia at 4 sites in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prostate Specific Antigen (PSA) response (time frame: Through study completion, up until 24 months after the last patient commences treatment.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03658447, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in